Masaki Igarashi

assistant professor

University of Tokyo Hospital
Country flagJapan

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (8)

Cigarette smoking is a well-known risk factor inducing the development and progression of various diseases. Nicotine (NIC) is the major constituent of cigarette smoke. However, knowledge of the mechanism underlying the NIC-regulated stem cell functions is limited. In this study, we demonstrate that NIC increases the abundance and proliferative activity of murine intestinal stem cells (ISCs) in vivo and ex vivo. Moreover, NIC induces Yes-associated protein (YAP) /Transcriptional coactivator with PDZ-binding motif (TAZ) and Notch signaling in ISCs via α7-nicotinic acetylcholine receptor (nAchR) and protein kinase C (PKC) activation; this effect was not detected in Paneth cells. The inhibition of Notch signaling by dibenzazepine (DBZ) nullified the effects of NIC on ISCs. NIC enhances in vivo tumor formation from ISCs after loss of the tumor suppressor gene Apc, DBZ inhibited NIC-induced tumor growth. Hence, this study identifies a NIC-triggered pathway regulating the stemness and tumorigenicity of ISCs and suggests the use of DBZ as a potential therapeutic strategy for treating intestinal tumors.

Year:

2025

Background A high intake of dietary fiber has been shown to improve glycemic control and decrease hyperinsulinemia in people living with type 2 diabetes (T2D). T2D patients in Japan consume less than the recommended amount of fiber. Based on findings from a formative study, we developed an artificial intelligence (AI)-powered mobile health (mHealth) intervention, FiberMore, that uses the theory of planned behavior to help T2D patients increase their dietary fiber intake by enhancing their perceived behavioral control and attitude toward fiber consumption. Objective We aimed to assess the efficacy of FiberMore in improving the dietary fiber intake of T2D patients by conducting a pilot randomized controlled trial. In addition, we want to explore the efficacy of FiberMore in reducing HbA 1c of T2D patients via improvement in dietary fiber intake. Methods This is a randomized, single-blinded, multicenter study targeting 80 T2D patients from 3 institutions in Japan with a 2-week run-in, a 12-week intervention, and a 12-week observation. The intervention group is given access to FiberMore throughout the 12-week intervention period. A core feature of FiberMore is AI-powered meal photo logging using a fine-tuned GPT-4o (OpenAI) model, which analyzes the nutrient content of meals and delivers personalized, real-time feedback on fiber content. In addition, FiberMore provides personalized fiber goal setting and supports participants in identifying barriers to increasing fiber intake, along with corresponding coping strategies (labeled as “solutions” to the participant), through an AI chatbot. The AI chatbot also assesses participants’ emotional attitudes toward eating more fiber and delivers relevant educational content on dietary fiber. The control group receives a sham intervention focused on salt reduction, consisting of educational content delivered at 3 time points during the intervention period and records their daily efforts in salt reduction in a diary. The 12-week intervention period will be followed by a 12-week observational period to investigate the sustainability of the intervention’s effects. The primary outcome is between-group difference in the change of dietary fiber intake at 12 weeks. The secondary outcomes include HbA1c, other clinical measures, measurements of behavior changes, and assessment of participants’ satisfaction and perceived usefulness of the intervention. Results Recruitment began on February 12, 2025, and ended on September 1, 2025. We anticipate that the intervention period will conclude in December 2025 and the observation period will conclude in March 2026. As of September 22, 2025, a total of 72 participants have been officially enrolled and randomized. Conclusions: There are currently no mHealth dietary interventions that specifically focus on increasing fiber intake in Japan, highlighting the novelty of this intervention. This trial will generate important evidence on the efficacy, feasibility, and safety of an AI-based mHealth intervention for enhancing dietary fiber intake and glycemic control in free-living individuals with T2D. Furthermore, as a pilot study, it will offer valuable insights into the development of AI as a promising tool for accurate, low-burden dietary assessment.

Year:

2025

Cigarette smoking is a well-known risk factor inducing the development and progression of various diseases. Nicotine (NIC) is the major constituent of cigarette smoke. However, knowledge of the mechanism underlying the NIC-regulated stem cell functions is limited. In this study, we demonstrate that NIC increases the abundance and proliferative activity of murine intestinal stem cells (ISCs) in vivo and ex vivo. Moreover, NIC induces Yes-associated protein (YAP) /Transcriptional coactivator with PDZ-binding motif (TAZ) and Notch signaling in ISCs via α7-nicotinic acetylcholine receptor (nAchR) and protein kinase C (PKC) activation; this effect was not detected in Paneth cells. The inhibition of Notch signaling by dibenzazepine (DBZ) nullified the effects of NIC on ISCs. NIC enhances in vivo tumor formation from ISCs after loss of the tumor suppressor gene Apc, DBZ inhibited NIC-induced tumor growth. Hence, this study identifies a NIC-triggered pathway regulating the stemness and tumorigenicity of ISCs and suggests the use of DBZ as a potential therapeutic strategy for treating intestinal tumors.

Year:

2025

Cigarette smoking is a well-known risk factor inducing the development and progression of various diseases. Nicotine (NIC) is the major constituent of cigarette smoke. However, knowledge of the mechanism underlying the NIC-regulated stem cell functions is limited. In this study, we demonstrate that NIC increases the abundance and proliferative activity of intestinal stem cells (ISCs) in vivo and ex vivo. Moreover, NIC induces Yes-associated protein (YAP) /Transcriptional coactivator with PDZ-binding motif (TAZ) and Notch signaling in ISCs via α7-nicotinic acetylcholine receptor (nAchR) and protein kinase C (PKC) activation; this effect was not detected in Paneth cells. The inhibition of Notch signaling by dibenzazepine (DBZ) nullified the effects of NIC on ISCs. NIC enhances in vivo tumor formation from ISCs after loss of the tumor suppressor gene Apc, DBZ inhibited NIC-induced tumor growth. Hence, this study identifies a NIC-triggered pathway regulating the stemness and tumorigenicity of ISCs and suggests the use of DBZ as a potential therapeutic strategy for treating intestinal tumors.

Year:

2024

Cigarette smoking is a well-known risk factor inducing the development and progression of various diseases. Nicotine (NIC) is the major constituent of cigarette smoke. However, knowledge of the mechanism underlying the NIC-regulated stem cell functions is limited. In this study, we demonstrate that NIC increases the abundance and proliferative activity of intestinal stem cells (ISCs) in vivo and ex vivo. Moreover, NIC induces Yes-associated protein (YAP) /Transcriptional coactivator with PDZ-binding motif (TAZ) and Notch signaling in ISCs via α7-nicotinic acetylcholine receptor (nAchR) and protein kinase C (PKC) activation; this effect was not detected in Paneth cells. The inhibition of Notch signaling by dibenzazepine (DBZ) nullified the effects of NIC on ISCs. NIC enhances in vivo tumor formation from ISCs after loss of the tumor suppressor gene Apc, DBZ inhibited NIC-induced tumor growth. Hence, this study identifies a NIC-triggered pathway regulating the stemness and tumorigenicity of ISCs and suggests the use of DBZ as a potential therapeutic strategy for treating intestinal tumors.

Year:

2024

Cigarette smoking is a well-known risk factor inducing the development and progression of various diseases. Nicotine (NIC) is the major constituent of cigarette smoke. However, knowledge of the mechanism underlying the NIC-regulated stem cell functions is limited. In this study, we demonstrate that NIC increases the abundance and proliferative activity of intestinal stem cells (ISCs) in vivo and ex vivo. Moreover, NIC induces Yes-associated protein (YAP)/Transcriptional coactivator with PDZ-binding motif (TAZ) and Notch signaling in ISCs via α7-nicotinic acetylcholine receptor (nAchR) and protein kinase C (PKC) activation; this effect was not detected in Paneth cells. The inhibition of Notch signaling by dibenzazepine (DBZ) nullified the effects of NIC on ISCs. NIC enhances in vivo tumor formation from ISCs after loss of the tumor suppressor gene Apc, DBZ inhibited NIC-induced tumor growth. Hence, this study identifies a NIC-triggered pathway regulating the stemness and tumorigenicity of ISCs and suggests the use of DBZ as a potential therapeutic strategy for treating intestinal tumors.

Year:

2024

Cigarette smoking is a well-known risk factor inducing the development and progression of various diseases. Nicotine (NIC) is the major constituent of cigarette smoke. However, knowledge of the mechanism underlying the NIC-regulated stem cell functions is limited. In this study, we demonstrate that NIC increases the abundance and proliferative activity of intestinal stem cells (ISCs) in vivo and ex vivo. Moreover, NIC induces Yes-associated protein (YAP) /Transcriptional coactivator with PDZ-binding motif (TAZ) and Notch signaling in ISCs via α7-nicotinic acetylcholine receptor (nAchR) and protein kinase C (PKC) activation; this effect was not detected in Paneth cells. The inhibition of Notch signaling by dibenzazepine (DBZ) nullified the effects of NIC on ISCs. NIC enhances in vivo tumor formation from ISCs after loss of the tumor suppressor gene Apc, DBZ inhibited NIC-induced tumor growth. Hence, this study identifies a NIC-triggered pathway regulating the stemness and tumorigenicity of ISCs and suggests the use of DBZ as a potential therapeutic strategy for treating intestinal tumors.

Year:

2024

Year:

2023

Collaborators (3)

Masaomi Nangaku

Graduate School of Medicine, The University of Tokyo

JAPAN
View details

Kayo Waki

Associate professor

University of Tokyo

JAPAN
View details

Toshimasa Yamauchi

Professor

Graduate School of Medicine, The University of Tokyo

JAPAN
View details